Abstract
BackgroundGlucocorticoids (GC) remain the mainstay of treatment in Systemic Lupus Erythematosus (SLE). Type I interferons (IFN), produced by plasmacytoid dendritic cells (pDC) in response to Toll-Like receptors (TLR) ligands, are...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
